Workshop on Innovation Towards an Artificial Pancreas
Current evidence demonstrates that when glycemic control is not optimized, diabetes imposes additional burdensome care requirements, health care costs, and high risk of disabling complications. It is expected that close to physiological glucose-metabolic control provided by an artificial pancreas will reduce the incidence of acute and chronic complications and significantly improve the quality of life of the individuals affected. As a consequence, further morbidity and mortality also may be prevented. The purpose of this workshop is to have a multidisciplinary discussion of advances and prospective areas of research that would accelerate the development and delivery of a wearable, automated artificial pancreas for individuals with diabetes. It will be focused on the following topics:
- State of the art: designs, results and challenges from the latest closed loop studies;
- Learning algorithms with more inputs and fault detection;
- Improved sensors;
- New hormones and delivery for improved kinetics;
- Innovative approaches in closing the loop;
- Elements for a new generation of devices/technologies.
FDA Arleen Pinkos, M.T.
JDRF Marlon Pragnell, Ph.D.
NIH Guillermo Arreaza, M.D.
Rich Bergenstal, M.D., Park Nicollet Health Services
Claudio Cobelli, Ph.D., Padova University, Italy
Barry Ginsberg, M.D., Ph.D., Diabetes Technology Consultants
David Klonoff, M.D., Mills Peninsula Health Services
Robert Vigersky, M.D., Walter Reed National Military Medical Center
Kenneth Ward, M.D., Legacy Research Institute
Mike Weiss, M.D., Case Western Reserve University and Thermalin, Inc.
Natalie Wisniewski, Ph.D., Medical Device Consultancy
Todd Zion, Ph.D., Akston Biosciences Corporation
Howard Zisser, M.D., Sansum Diabetes Research Institute